ReviewJournal of the American Academy of Dermatology2019
Hair disorders in patients with cancer.
Review in Journal of the American Academy of Dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 4 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Adverse effects of scalp cooling for the reduction of chemotherapy-induced alopecia: A systematic review and meta-analysis.Breast cancer research and treatment · 2025Pooled it
- Effects of exercise on life satisfaction of people diagnosed with cancer: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Pooled it
- The scalp cooling therapy for hair loss in breast cancer patients undergoing chemotherapy: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Pooled it
- Effects of high-intensity training on the quality of life of cancer patients and survivors: a systematic review with meta-analysis.Scientific reports · 2021Pooled it
- The efficacy of scalp cooling in patients receiving chemotherapy for primary gynecologic cancers: a randomized controlled trial.Scientific reports · 2026Trial
- Pigmentary Changes Reported with Tyrosine Kinase Inhibitors: A Narrative Review of Mechanisms and Clinical Implications.Clinical drug investigation · 2026Review
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody-drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling.International journal of molecular sciences · 2026Review
- Hitting pause on chemotherapy-induced alopecia: transient p53 activation as a guardian of the hair follicle.The Journal of clinical investigation · 2026Article
- Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!American journal of clinical dermatology · 2026Review
- Stingless bee propolis promotes hair follicle regeneration and melanocyte function in chemotherapy-induced alopecia mouse model.Experimental animals · 2026Article
- The Developmental Trajectory of Learned Helplessness in Breast Cancer Chemotherapy Patients: A Longitudinal Study Based on Latent Growth Models.Patient preference and adherence · 2026Article
- Expression Characteristics of PAX7 and Its Prognostic Correlation in Breast Cancer.The breast journal · 2026Article
- Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.American journal of clinical dermatology · 2026Review
- The Early Cost-Effectiveness of a Novel Scalp Cooling Device to Alleviate Chemotherapy-Induced Alopecia in Patients with Early Breast Cancer.ClinicoEconomics and outcomes research : CEOR · 2026Article
- The use of oral dutasteride, minoxidil, and finasteride for treating endocrine therapy-induced hair loss from breast cancer treatment: A case series study.JAAD case reports · 2026Article
- Preferences and reasons for clothing colors in women patients and survivors of breast cancer in Korea.PloS one · 2026Article
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies.Biomedicines · 2025Review
- Liriodendron attenuates intestinal fibrosis and inflammation in mice with radiation proctopathy.Chinese medicine · 2025Article
- Alopecia in Children with Cancer: A Review from Pathophysiology to Management.American journal of clinical dermatology · 2025Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
Abstract
Cytotoxic chemotherapies, molecularly targeted therapies, immunotherapies, radiotherapy, stem cell transplants, and endocrine therapies may lead to hair disorders, including alopecia, hirsutism, hypertrichosis, and pigmentary and textural hair changes. The mechanisms underlying these changes are varied and remain incompletely understood, hampering the development of preventive or therapeutic guidelines. The psychosocial impact of chemotherapy-induced alopecia has been well documented primarily in the oncology literature; however, the effect of other alterations, such as radiation-induced alopecia, hirsutism, and changes in hair color or texture on quality of life have not been described. This article reviews clinically significant therapy-related hair disorders in oncology patients, including the underlying pathophysiological mechanisms, severity grading scales, patient-reported quality of life questionnaires, management strategies, and future translational research opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.